
Enovis Corp (ENOV) Stock Forecast & Price Target
Enovis Corp (ENOV) Analyst Ratings
Bulls say
Enovis Corp has demonstrated positive financial momentum, with its adjusted gross margin increasing by 150 basis points year-over-year, reaching 60.1%, which surpassed consensus estimates. The company also reported significant growth in its Reconstructive segment, with proforma sales rising by 10.0% to $274.0 million in the fourth quarter of 2024, reflecting an improvement over the prior quarter's growth. Furthermore, the expectation of continued increases in gross and operating margins, alongside anticipated accretive acquisitions, supports a favorable outlook for Enovis's EBITDA and EPS growth outpacing revenue growth.
Bears say
Enovis Corp is facing a negative outlook primarily due to decreasing revenue estimates, with projections for 2024 and 2025 adjusted down to $2.100 billion and $2.244 billion, respectively. Additionally, the company's Prevention & Recovery segment has experienced growth deceleration, and there are identified risks including potential market share loss to competitors and slow growth in the orthopedic market. Furthermore, ongoing dissynergies related to Lima have created notable headwinds, impacting overall financial performance and stability.
This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.
Enovis Corp (ENOV) Analyst Forecast & Price Prediction
Start investing in Enovis Corp (ENOV)
Order type
Buy in
Order amount
Est. shares
0 shares